<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3867">
  <stage>Registered</stage>
  <submitdate>14/02/2013</submitdate>
  <approvaldate>14/02/2013</approvaldate>
  <nctid>NCT01795781</nctid>
  <trial_identification>
    <studytitle>Assays for and Reversal of New Anticoagulants</studytitle>
    <scientifictitle>Development of Anticoagulant Assays for New Anticoagulants and Their Reversibility in Vitro</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011/117</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <healthcondition>Osteoarthritis of the Knee</healthcondition>
    <healthcondition>Osteoarthritis of the Hip</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients receiving a new anticoagulant - Patients are receiving dabigatran for atrial fibrillation or rivaroxaban for osteoarthritis of hip or knee undergoing total hip or knee replacement respectively

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ability to reverse anticoagulant effect in vitro of dabigatran or rivarovaban - The ability of nonspecific coagulation factors to reverse anticoagulant effect in vitro as measured by dilute thrombin time, Calibrated automated thrombinoscope, thromboelastogram and Rotem</outcome>
      <timepoint>Two hours after ingestion of anticoagulant dose</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Receiving dabigatran for atrial fibrillation

          -  Or,for osteoarthritis of the hip or knee receiving rivaroxaban to prevent
             thromboembolic disease after total hip or knee replacement respectively</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Failure to sign informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>R.P.Herrmann</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>New anticoagulants are being introduced to replace warfarin. These drugs do not require
      monitoring and are safer. There is currently no recommended way to reverse these drugs
      rapidly in the event of undue bleeding or need for emergency surgery. This is a lab study to
      look at ways to reverse the drugs rapidly</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01795781</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ross I Baker, MB, BS</name>
      <address>Royal Perth Hospital, Wellington St, Perth, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>